A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

Inclusion Criteria: * Patients must have a positive skin prick test for grass pollen allergen. * Positive skin prick test to positive histamine control * Negative skin prick test to negative control * Specific IgE for grass pollen as documented by ImmunoCAP test with class ≥ 2 * A history of moderate to severe symptoms of seasonal allergic rhinitis and/or conjunctivitis due to grass (Pooideae) pollen exposure that required repeated use of antihistamines, nasal steroids, and/or leukotriene modifiers for relief of symptoms during the last two consecutive seasons prior to the study * Males or non-pregnant, non-lactating females who are not of child-bearing potential or using effective contraception * Patients who are normally active and otherwise judged to be in good health * For patients with a history of asthma, forced expiratory volume in 1 second (FEV1) ≥ 80% of National Health and Nutrition Examination Surveys (NHANES) predicted, with a FEV1/forced vital capacity (FVC) ratio ≥ 70%. * Able to observe the drug washout times listed in the Prohibited Medications Table below prior to screening * Patients willing and able to attend required study visits and able to follow the protocol requirements. * Patients willing and able to give written informed consent. Exclusion Criteria: * Symptoms outside the grass pollen season due to a perennial and/or non-grass seasonal allergen, if the patient is unable to avoid the offending allergen. * Immunological disorders or other diseases t…